Joel Barrish, PhD

Advisor

Joel Barrish is a veteran biotech leader with decades of experience in drug discovery, has advanced more than 40 clinical compounds through various stages of development, and co-invented a major oncology therapy. He has led two successful company exits as CSO, most recently Jnana Therapeutics (acquired by Roche for up to $1.1B), a company focused on unlocking hard-to-drug targets such as solute carrier proteins (SLCs), and previously Achillion Pharmaceuticals (acquired by AstraZeneca for up to $1.1B), which developed complement pathway inhibitors for rare diseases. Joel’s pioneering work in kinase inhibitor research and innovation in hard-to-drug targets has significantly shaped the fields of immunology and oncology. He is deeply engaged in the RA Capital ecosystem and currently serves as CEO of two Raven companies, Conveyor Therapeutics and Avilar Therapeutics.